The Valley Desk

NCT04485260 · Interventional trial

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Overall registry status Unknown

Phase 1 · Phase 2

Conditions Myelofibrosis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov